试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
Melatonin for Adolescent Migraine Prevention Study
编号:NCT03150797登记状态:提前终止企业 / 申办者:Amy Gelfand
药物 / 成分:Melatonin、Placebo oral capsule
登记的停止原因(原文):Insufficient Fund
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
编号:NCT03330405登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Avelumab Phase 1b、Talazoparib Phase 1b、Avelumab Phase 2、Talazoparib Phase 2
登记的停止原因(原文):The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
编号:NCT03690154登记状态:提前终止企业 / 申办者:Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
药物 / 成分:FN-1501
登记的停止原因(原文):Despite demonstrated safety and tolerability the trial was terminated early due to program re-prioritization in light of the competitive landscape.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
编号:NCT03947255登记状态:提前终止企业 / 申办者:Seagen Inc.
药物 / 成分:brentuximab vedotin
登记的停止原因(原文):Study stopped early due to low patient accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-13
The Effect of Donepezil on Glycemic Control in Type II Diabetics
编号:NCT04507438登记状态:提前终止企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Donepezil 5-10 Mg Oral Tablet、Placebo Oral Tablet
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-12
Testosterone and Alendronate in Hypogonadal Men
编号:NCT01460654登记状态:提前终止企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Testosterone、Alendronate、Placebo Alendronate、Placebo Testosterone
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-12
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
编号:NCT03266991登记状态:提前终止企业 / 申办者:Aarhus University Hospital
药物 / 成分:Rifapentine、Isoniazid
登记的停止原因(原文):Recruitment issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-12
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
编号:NCT03490760登记状态:提前终止企业 / 申办者:Baptist Health South Florida
药物 / 成分:Durvalumab、Radiation Therapy
登记的停止原因(原文):Slow/poor enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-12
Effects of Psilocybin in Concussion Headache
编号:NCT03806985登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Placebo oral capsule、Low Dose Psilocybin、High Dose Psilocybin
登记的停止原因(原文):Challenging to recruit qualifying subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
编号:NCT04598321登记状态:提前终止企业 / 申办者:Brown University
药物 / 成分:Talazoparib Oral Capsule
登记的停止原因(原文):termination of research grant agreement
查看官方原始记录 ↗